Inside Vertex Pharmaceuticals’ Clinical Pipeline
In March 2017, Vertex Pharmaceuticals (VRTX) announced promising results from two phase-3 clinical trials, Evolve and Expand.
Vertex (VRTX) has planned to submit a new drug application to the FDA in 3Q17 for a Tezacaftor-Ivacaftor combination treatment for cystic fibrosis.
In 2016, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $979 million, reflecting ~180% YoY (year-over-year) growth.
In 2016, Vertex Pharmaceuticals’ (VRTX) Kalydeco reported revenues of around $703 million, which represents ~11% growth on a YoY (year-over-year) basis.
In 2016, Vertex Pharmaceuticals (VRTX) reported revenues of around ~$1.7 billion, which reflected a whopping 65% YoY (year-over-year) growth.
In 2016, Celgene’s (CELG) Otezla generated revenues of around $1.0 billion, a 116% year-over-year (or YoY) increase.
Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.
Celgene has entered a strategic collaboration with Acceleron for the development of luspatercept.
In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.
In 2016, Celgene’s (CELG) Pomalyst crossed the $1 billion sales mark.
In 2016, Celgene’s (CELG) Abraxane reported revenues of ~$973 million, which is ~1% year-over-year (or YoY) growth.
In 1Q17, Celgene (CELG) reported revenues of ~$3.0 billion, an increase of ~18% year-over-year (or YoY).
If Kevzara is approved in major international markets, it may have a favorable impact on Regeneron stock.
Regeneron (REGN) has obtained positive results from its Phase 2 proof-of-concept study evaluating Dupixent in eosinophilic esophagitis.
Regeneron plans to discuss Dupixent’s innovative mechanism-based treatment approach with regulatory authorities.
Regeneron (REGN) and Sanofi (SNY) are exploring the use of Dupixent in other indications such as asthma, pediatric AD, nasal polyps, and eosinophilic esophagitis.
After Dupixent’s commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.
To further expand Eylea’s label, Regeneron is studying the drug in combination with angiopoietin2 (or Ang2) antibody nesvacumab in two Phase 2 trials.
Regeneron Pharmaceuticals (REGN) is committed to maintaining leadership in the anti-VEGF market with its market-leading drug Eylea.
In 1Q17, Regeneron’s (REGN) Eylea reported revenues of about $854.0 million in the US market, which is a YoY (year-over-year) rise of about 9.0%.